Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference
November 23 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that the
Company’s management team will participate in a fireside chat at
the 4th Annual Evercore ISI HealthCONx Conference on Wednesday,
December 1, 2021, at 2:40 p.m. ET.
A live webcast of the presentation will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. XMT-1592, Mersana’s second ADC product candidate
targeting NaPi2b-expressing tumors, was created using Mersana’s
customizable and homogeneous Dolasynthen platform and is in the
dose escalation portion of a Phase 1 proof-of-concept clinical
study. The Company’s early-stage programs include XMT-1660, a
Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform and targeting a novel epitope of human epidermal growth
factor receptor 2 (HER2). In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:
Investor & Media ContactSarah
Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024